Atherosclerosis Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atherosclerosis pipeline constitutes 25+ key companies continuously working towards developing 25+ Atherosclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Atherosclerosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atherosclerosis Market.

The Atherosclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Atherosclerosis Pipeline Report: https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Atherosclerosis treatment therapies with a considerable amount of success over the years.
• Atherosclerosis companies working in the treatment market are ImmunoPrecise Antibodies, Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen, Novo Nordisk, CSL Behring, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others, are developing therapies for the Atherosclerosis treatment
• Emerging Atherosclerosis therapies in the different phases of clinical trials are- TATX-21, Epeleuton, VERVE-101, SLN360, MK-0616, REG-001, Olpasiran, Ziltivekimab, CSL300, Inclisiran, Ertugliflozin, Olpasiran, Olezarsen, Obicetrapib, Tetrahydrobiopterin, MEDI6570, GFH312, and others are expected to have a significant impact on the Atherosclerosis market in the coming years.
• In December 2022, Amgen will initiate double-blind, randomized, placebo-controlled, multicenter studyassessing the impact of Olpasiran on major cardiovascular events in participants with Atherosclerotic CardiovascularDisease and Elevated Lipoprotein(a)

Atherosclerosis Overview
Atherosclerosis is a condition where the arteries become narrowed and hardened due to a buildup of plaque. Plaque is made up of fatty substances, cholesterol, cellular waste products, calcium, and fibrin (a clotting material) that accumulate in the inner lining of arteries. Over time, this buildup can restrict blood flow to organs and tissues throughout the body.

Get a Free Sample PDF Report to know more about Atherosclerosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Atherosclerosis Drugs Under Different Phases of Clinical Development Include:
• TATX-21: ImmunoPrecise Antibodies
• Epeleuton: Afimmune
• VERVE-101: Verve Therapeutics
• SLN360: Silence Therapeutics
• MK-0616: Merck Sharp & Dohme LLC
• REG-001: Regio Bioscience
• Olpasiran: Amgen
• Ziltivekimab: Novo Nordisk
• CSL300: CSL Behring
• Inclisiran: Novartis Pharmaceuticals
• Ertugliflozin: Merck Sharp & Dohme LLC
• Olpasiran: Amgen
• Olezarsen: Ionis Pharmaceuticals, Inc.
• Obicetrapib: NewAmsterdam Pharma
• Tetrahydrobiopterin: BioMarin Pharmaceutical
• MEDI6570: AstraZeneca
• GFH312: Zhejiang Genfleet Therapeutics Co., Ltd.

Atherosclerosis Route of Administration
Atherosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Atherosclerosis Molecule Type
Atherosclerosis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Atherosclerosis Pipeline Therapeutics Assessment
• Atherosclerosis Assessment by Product Type
• Atherosclerosis By Stage and Product Type
• Atherosclerosis Assessment by Route of Administration
• Atherosclerosis By Stage and Route of Administration
• Atherosclerosis Assessment by Molecule Type
• Atherosclerosis by Stage and Molecule Type

DelveInsight's Atherosclerosis Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Atherosclerosis product details are provided in the report. Download the Atherosclerosis pipeline report to learn more about the emerging Atherosclerosis therapies
https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Atherosclerosis Therapeutics Market include:
Key companies developing therapies for Atherosclerosis are - SL Behring, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others.

Atherosclerosis Pipeline Analysis:
The Atherosclerosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Atherosclerosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atherosclerosis Treatment.
• Atherosclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atherosclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atherosclerosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Atherosclerosis drugs and therapies
https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atherosclerosis Pipeline Market Drivers
• Rising prevalence of cardiovascular diseases, growing number of geriatric population, increase in the number of research and development activities are some of the important factors that are fueling the Atherosclerosis Market.

Atherosclerosis Pipeline Market Barriers
• However, high cost associated with the treatment, lack of awareness among people and other factors are creating obstacles in the Atherosclerosis Market growth.

Scope of Atherosclerosis Pipeline Drug Insight
• Coverage: Global
• Key Atherosclerosis Companies: ImmunoPrecise Antibodies, Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen, Novo Nordisk, CSL Behring, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others
• Key Atherosclerosis Therapies: TATX-21, Epeleuton, VERVE-101, SLN360, MK-0616, REG-001, Olpasiran, Ziltivekimab, CSL300, Inclisiran, Ertugliflozin, Olpasiran, Olezarsen, Obicetrapib, Tetrahydrobiopterin, MEDI6570, GFH312, and others
• Atherosclerosis Therapeutic Assessment: Atherosclerosis current marketed and Atherosclerosis emerging therapies
• Atherosclerosis Market Dynamics: Atherosclerosis market drivers and Atherosclerosis market barriers

Request for Sample PDF Report for Atherosclerosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Atherosclerosis Report Introduction
2. Atherosclerosis Executive Summary
3. Atherosclerosis Overview
4. Atherosclerosis- Analytical Perspective In-depth Commercial Assessment
5. Atherosclerosis Pipeline Therapeutics
6. Atherosclerosis Late Stage Products (Phase II/III)
7. Atherosclerosis Mid Stage Products (Phase II)
8. Atherosclerosis Early Stage Products (Phase I)
9. Atherosclerosis Preclinical Stage Products
10. Atherosclerosis Therapeutics Assessment
11. Atherosclerosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Atherosclerosis Key Companies
14. Atherosclerosis Key Products
15. Atherosclerosis Unmet Needs
16 . Atherosclerosis Market Drivers and Barriers
17. Atherosclerosis Future Perspectives and Conclusion
18. Atherosclerosis Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports by DelveInsight

Cart-related Neurotoxicity Market https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market
DelveInsight's "CART-related Neurotoxicity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the CART-related Neurotoxicity, historical and forecasted epidemiology as well as the CART-related Neurotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

H3n2 Infection Market
https://www.delveinsight.com/report-store/h3n2-infection-market
DelveInsight's "H3N2 Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the H3N2 Infection, historical and forecasted epidemiology as well as the H3N2 Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market
DelveInsight's "Liver Angiosarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Liver Angiosarcoma, historical and forecasted epidemiology as well as the Liver Angiosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Trastuzuma Biosimilar
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight's, "Trastuzumab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
DelveInsight's "Undifferentiated Pleomorphic Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Undifferentiated Pleomorphic Sarcoma, historical and forecasted epidemiology as well as the Undifferentiated Pleomorphic Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.